Abstract: A telematics system and method thereof with mobile telematics devices associated with a plurality of motor vehicles. The telematics devices include one or more wireless connections or wired connections, and a plurality of interfaces to connect with at least one of a data transmission bus of a motor vehicle, and/or a plurality of interfaces to connect with sensors and/or measuring devices and/or speakers and/or microphones. To provide a wireless connection, at least one of the mobile telematics devices acts as a wireless node within a corresponding data transmission network by way of antenna connections of the mobile telematics device. At least one of the mobile telematics devices is connected to an on-board diagnostic system (OBD) and/or an in-car interactive device and/or a monitoring cellular mobile node application, and wherein at least one of the mobile telematics devices capture usage-based and/or user-based telematics data of a motor vehicle and/or user.

Abstract: The invention relates to a method of determining an infection of a patient with Pseudomonas species potentially resistant to antimicrobial drug treatment, a method of selecting a treatment of a patient suffering from an antibiotic resistant Pseudomonas infection, and a method of determining an antibiotic resistance profile for bacterial microorganisms of Pseudomonas species, as well as computer program products used in these methods. In an exemplary method, a sample 1, is used for molecular testing 2, and then a molecular fingerprint 3 is taken. The result is then compared to a reference library 4, and the result 5 is reported.

Abstract: The present invention relates to novel isolated nucleic acid molecules (novel miRNAs and novel miRNA precursor molecules) as well as vectors, host cells, primers, cDNA-transcripts, polynucleotides derived from said isolated nucleic acid molecules and their use in diagnosis and therapy. Furthermore the present invention relates to methods and kits for diagnosing a disease, such as Multiple Sclerosis (MS) or Alzheimer's Disease (AD) employing said novel isolated nucleic acid molecules (novel miRNAs molecules).

Abstract: The present invention relates to a process for the preparation of an optically active carbonyl compound by asymmetric hydrogenation of a prochiral ?,?-unsaturated carbonyl compound with hydrogen in the presence of at least one optically active transition metal catalyst that is soluble in the reaction mixture and which has rhodium as catalytically active transition metal and a chiral, bidentate bisphosphine ligand, wherein the reaction mixture during the hydrogenation of the prochiral ?,?-unsaturated carbonyl compound additionally comprises at least one compound of the general formula (I): in which R1, R2: are identical or different and are C6- to C10-aryl which is unsubstituted or carries one or more, e.g. 1, 2, 3, 4 or 5, substituents which are selected from C1- to C6-alkyl, C3- to C6-cycloalkyl, C6- to C10-aryl, C1- to C6-alkoxy and amino; Z is a group CHR3R4 or aryl which is unsubstituted or carries one or more, e.g.

Abstract: A securing device for removably attaching a device to two mutually spaced head support rods (1a, 1b) of a motor vehicle seat (1), having a receiving bushing (3e) for receiving a plug element (2a) which is arranged on the device (2) and having a first and a second securing element (3, 3?, 4, 4?) with which the receiving bushing (3e) can be secured on the head support rods (1a, 1b). The first and the second securing element (3, 3?, 4, 4?) are formed on opposing sides for arranging on the head support rods (1a, 1b), and connectors (5, 5a, 5b) are provided for reciprocally connecting the securing elements (3, 3?, 4, 4?), wherein sliding elements (6a, 6b) are arranged between the securing elements (3, 3?, 4, 4?) and the head support rods (1a, 1b).

Abstract: The present invention relates to a method for preparing 2?-O-fucosyllactose, the 2?-O-fucosyllactose obtainable by this method and the use thereof. The method comprises reacting the persilylated, protected fucose derivatives of the formula (I) below, with at least one tri(C1-C6-alkyl)silyl iodide and subsequently reacting the product thus obtained with the compound of the general formula (II), in the presence of a base. In the formulae (I) and (II), the variables are each defined as follows: RSi are the same or different and are a residue of the formula SiRaRbRc; R1 is a C(?O)—R11 residue or an SiR12R13R14 residue, R2 are the same or different and are C1-C8-alkyl or together form a linear C3-C6-alkanediyl, which is unsubstituted or has 1 to 6 methyl groups as substituents; R3 are the same or different and are C1-C8-alkyl or together form a linear C1-C4-alkanediyl, which is unsubstituted or has 1 to 6 methyl groups as substituents.

Abstract: The invention relates to a method of determining an infection of a patient with Morganella species potentially resistant to antimicrobial drug treatment, a method of selecting a treatment of a patient suffering from an antibiotic resistant Morganella infection, and a method of determining an antibiotic resistance profile for bacterial microorganisms of Morganella species, as well as computer program products used in these methods. In an exemplary method, a sample 1, is used for molecular testing 2, and then a molecular fingerprint 3 is taken. The result is then compared to a reference library 4, and the result 5 is reported.

Abstract: The invention relates to a method of determining an infection of a patient with Stenotrophomonas species potentially resistant to antimicrobial drug treatment, a method of selecting a treatment of a patient suffering from an antibiotic resistant Stenotrophomonas infection, and a method of determining an antibiotic resistance profile for bacterial microorganisms of Stenotrophomonas species, as well as computer program products used in these methods. In an exemplary method, a sample 1, is used for molecular testing 2, and then a molecular fingerprint 3 is taken. The result is then compared to a reference library 4, and the result 5 is reported.

Abstract: A caliper comprising: (a) an inboard side; (b) an outward side, wherein the inboard side and the outboard side include three or more bores that are radially staggered relative to two or more of the bores; and (c) a pocket located within a central region of the inboard side, the outboard side, or both; wherein the bores on the inboard side, the outboard side, or both are positioned so that: (i) all of the bores are located entirely radially below the pocket; (ii) none of the bores are located below the pocket; (iii) one or more of the bores are located partially radially below the pocket; (iv) one or more of the bores are located entirely radially below the pocket; (v) one or more of the bores are not located partially or entirely radially below the pocket; or (vi) a combination of (iii) through (v).

Abstract: The invention relates to a method of determining an infection of a patient with Acinetobacter species potentially resistant to antimicrobial drug treatment, a method of selecting a treatment of a patient suffering from an antibiotic resistant Acinetobacter infection, and a method of determining an anti-biotic resistance profile for bacterial microorganisms of Acinetobacter species, as well as computer program products used in these methods. In an exemplary method, a sample 1, is used for molecular testing 2, and then a molecular finger-print 3 is taken. The result is then compared to a reference library 4, and the result 5 is reported.

Abstract: The invention relates to methods for diagnosing Parkinson's Disease PAD) with miRNA markers. Towards the identification of biomarkers for diagnosis of PD, a comprehensive analysis of miRNA expression patterns was obtained. Significantly deregulated miRNAs were identified.

Abstract: A process for preparing 2,6-dimethyl-5-heptenal, comprising oxidizing citral of which more than 50% are present as geranial with hydrogen peroxide in the presence of a catalyst comprising a Baeyer-Villiger oxidation catalyst, preferably a tin-containing molecular sieve.

Abstract: The present invention provides novel methods for diagnosing diseases based on the determination of specific miRNAs that have altered expression levels in disease states compared to healthy controls.

Abstract: The invention relates to a method of determining an infection of a patient with Shigella species potentially resistant to antimicrobial drug treatment, a method of selecting a treatment of a patient suffering from an antibiotic resistant Shigella infection, and a method of determining an antibiotic resistance profile for bacterial microorganisms of Shigella species, as well as computer program products used in these methods. In an exemplary method, a sample 1, is used for molecular testing 2, and then a molecular fingerprint 3 is taken. The result is then compared to a reference library 4, and the result 5 is reported.

Abstract: The present invention relates to a process for the preparation of an optically active carbonyl compound by asymmetric hydrogenation of a prochiral ?,?-unsaturated carbonyl compound with hydrogen in the presence of at least one optically active transition metal catalyst that is soluble in the reaction mixture and which has rhodium as catalytically active transition metal and a chiral, bidentate bisphosphine ligand, wherein the reaction mixture during the hydrogenation of the prochiral ?,?-unsaturated carbonyl compound additionally comprises at least one compound of the general formula (I): in which R1, R2: are identical or different and are C6- to C10-aryl which is unsubstituted or carries one or more, e.g. 1, 2, 3, 4 or 5, substituents which are selected from C1- to C6-alkyl, C3- to C6-cycloalkyl, C6- to C10-aryl, C1- to C6-alkoxy and amino; Z is a group CHR3R4 or aryl which is unsubstituted or carries one or more, e.g.

Abstract: The present invention provides novel methods for diagnosing diseases based on the determination of specific miRNAs that have altered expression levels in disease states compared to healthy controls.

Abstract: The present invention relates to a process for the preparation of an optically active carbonyl compound by asymmetric hydrogenation of a prochiral ?,?-unsaturated carbonyl compound with hydrogen in the presence of at least one optically active transition metal catalyst that is soluble in the reaction mixture and which has rhodium as catalytically active transition metal and a chiral, bidentate bisphosphine ligand, wherein the reaction mixture during the hydrogenation of the prochiral ?,?-unsaturated carbonyl compound additionally comprises at least one compound of the general formula (I): in which R1, R2: are identical or different and are C6- to C10-aryl which is unsubstituted or carries one or more, e.g. 1, 2, 3, 4 or 5, substituents which are selected from C1- to C6-alkyl, C3- to C6-cycloalkyl, C6- to C10-aryl, C1- to C6-alkoxy and amino; Z is a group CHR3R4 or aryl which is unsubstituted or carries one or more, e.g.

Abstract: The present invention relates to a method for diagnosis of a change of the status of health of a subject based on the determination of expression profiles of miRNAs.

Abstract: The present invention relates to a process for reacting isopulegol to menthone in the gas phase and to the use of the reaction products thus prepared as additives in foods, cosmetics, pharmaceutical products, tobacco formulations, household products, and laundry care products.